• Je něco špatně v tomto záznamu ?

Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss

J. Szilasiová, P. Mikula, J. Rosenberger, M. Fedičová, Z. Gdovinová, P. Urban, L. Frigová

. 2021 ; 27 (13) : 2023-2030. [pub] 20210226

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012019

BACKGROUND: The research is focused on sensitive biomarkers in multiple sclerosis (MS). OBJECTIVE: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA (no evident disease activity), including brain volumetry, in a cohort of MS patients treated with disease-modifying treatment (DMT). METHODS: Levels of pNfL (Single Molecule Array (SIMOA) technology) were examined in 95 RRMS (relapsing-remitting multiple sclerosis) patients and analyzed in relationship to NEDA-3 status and NEDA-BVL (brain volume loss; NEDA-3 extended by brain volumetry) during the last 12 months. The statistical model was developed using logistic regression analysis, including the independent variables: demographic, clinical, and magnetic resonance imaging (MRI) data. Dependent variables were NEDA-3 and NEDA-BVL status. RESULTS: The mean age of the study participants (n = 95, 62% females) was 37.85 years (standard deviation (SD) = 9.62) and the median disability score was 3.5 (2.5-4.1). Receiver operating characteristics (ROC) analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 92% and 78%, respectively, p < 0.001) and NEDA-BVL status (the sensitivity and specificity were 80% and 65%, respectively, p < 0.001). CONCLUSION: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-BVL status, including brain MRI-volumetry in patients with RRMS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012019
003      
CZ-PrNML
005      
20230117095601.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1352458521998039 $2 doi
035    __
$a (PubMed)33635154
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Szilasiová, Jarmila $u Department of Neurology, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic/Department of Neurology, L. Pasteur University Hospital, Košice, Slovak Republic
245    10
$a Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss / $c J. Szilasiová, P. Mikula, J. Rosenberger, M. Fedičová, Z. Gdovinová, P. Urban, L. Frigová
520    9_
$a BACKGROUND: The research is focused on sensitive biomarkers in multiple sclerosis (MS). OBJECTIVE: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA (no evident disease activity), including brain volumetry, in a cohort of MS patients treated with disease-modifying treatment (DMT). METHODS: Levels of pNfL (Single Molecule Array (SIMOA) technology) were examined in 95 RRMS (relapsing-remitting multiple sclerosis) patients and analyzed in relationship to NEDA-3 status and NEDA-BVL (brain volume loss; NEDA-3 extended by brain volumetry) during the last 12 months. The statistical model was developed using logistic regression analysis, including the independent variables: demographic, clinical, and magnetic resonance imaging (MRI) data. Dependent variables were NEDA-3 and NEDA-BVL status. RESULTS: The mean age of the study participants (n = 95, 62% females) was 37.85 years (standard deviation (SD) = 9.62) and the median disability score was 3.5 (2.5-4.1). Receiver operating characteristics (ROC) analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 92% and 78%, respectively, p < 0.001) and NEDA-BVL status (the sensitivity and specificity were 80% and 65%, respectively, p < 0.001). CONCLUSION: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-BVL status, including brain MRI-volumetry in patients with RRMS.
650    _2
$a dospělí $7 D000328
650    _2
$a mozek $x diagnostické zobrazování $7 D001921
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intermediární filamenta $7 D007382
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    12
$a roztroušená skleróza $x diagnostické zobrazování $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x diagnostické zobrazování $7 D020529
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mikula, Pavol, $u Department of Social and Behavioural Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic $d 1988- $7 xx0280701
700    1_
$a Rosenberger, Jaroslav $u Department of Health Psychology and Methodology of Research, II. Internal Clinic, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic/Olomouc University Social Health Institute, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Fedičová, Miriam $u Department of Neurology, L. Pasteur University Hospital, Košice, Slovak Republic
700    1_
$a Gdovinová, Zuzana $u Department of Neurology, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic/Department of Neurology, L. Pasteur University Hospital, Košice, Slovak Republic
700    1_
$a Urban, Peter $u Department of Medical and Clinical Biochemistry, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
700    1_
$a Frigová, Lýdia $u Pro Magnet, Košice, Slovak Republic $7 xx0280692
773    0_
$w MED00006389 $t Multiple sclerosis $x 1477-0970 $g Roč. 27, č. 13 (2021), s. 2023-2030
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33635154 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20230117095558 $b ABA008
999    __
$a ok $b bmc $g 1789559 $s 1163220
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c 13 $d 2023-2030 $e 20210226 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20220425
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace